Opdivo vs Eylea
Side-by-side drug price comparison from Medicare Part D data
Verdict
Eylea costs 95% less per claim than Opdivo ($752.00 vs $15821.00). Opdivo has a generic alternative available. Total Medicare spending: Opdivo at $5.1B vs Eylea at $3.7B.
| Metric | Opdivo | Eylea |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $15,821 | $752* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $5.1B | $3.7B |
| Total Claims | 324,000 | 4,860,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 15.8% | -8.3%* |
| Generic Available | Yes | Yes |
| Condition | Cancer | Eye Diseases |
| Total Beneficiaries | 66,000 | 685,000 |
Eylea costs 95% less per claim than Opdivo ($752.00 vs $15821.00). Opdivo has a generic alternative available. Total Medicare spending: Opdivo at $5.1B vs Eylea at $3.7B.
Explore More
Comparing Opdivo and Eylea on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.